NASDAQ:TPTXTurning Point Therapeutics Stock Price, Forecast & News

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 55.4% and is now trading at $62.98. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Turning Point Therapeutics.

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Turning Point Therapeutics.

Turning Point Therapeutics (NASDAQ:TPTX) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $1.03. View Turning Point Therapeutics' earnings history.

7 equities research analysts have issued 12 month target prices for Turning Point Therapeutics' stock. Their forecasts range from $56.00 to $88.00. On average, they anticipate Turning Point Therapeutics' stock price to reach $69.00 in the next year. This suggests a possible upside of 9.6% from the stock's current price. View analysts' price targets for Turning Point Therapeutics.

Press coverage about TPTX stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Turning Point Therapeutics earned a news impact score of -1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutTurning Point Therapeutics.

Some companies that are related to Turning Point Therapeutics include Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB) and Evotec (EVTCY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include AbbVie (ABBV), Pfizer (PFE), Enterprise Products Partners (EPD), GlaxoSmithKline (GSK), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Energy Transfer LP Unit (ET), General Mills (GIS), Intel (INTC) and Johnson & Johnson (JNJ).

(TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (8.51%), BlackRock Inc. (5.88%), Wellington Management Group LLP (4.31%), State Street Corp (2.98%), Lord Abbett & CO. LLC (2.74%) and Jennison Associates LLC (1.75%). Company insiders that own Turning Point Therapeutics stock include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Simeon George and Yi Larson. View institutional ownership trends for Turning Point Therapeutics.

TPTX stock was sold by a variety of institutional investors in the last quarter, including venBio Partners LLC, Cormorant Asset Management LP, Perceptive Advisors LLC, Perceptive Advisors LLC, Morgan Stanley, Wells Fargo & Company MN, Pictet Asset Management Ltd., and ArrowMark Colorado Holdings LLC. View insider buying and selling activity for Turning Point Therapeutics.

TPTX stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, MPM Oncology Impact Management LP, Lord Abbett & CO. LLC, Eagle Asset Management Inc., Aviva PLC, Jennison Associates LLC, Emerald Advisers LLC, and Burrage Capital Management LLC. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George, and Yi Larson. View insider buying and selling activity for Turning Point Therapeutics.

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TPTX stock can currently be purchased for approximately $62.98.

Turning Point Therapeutics has a market capitalization of $2.26 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe.

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]